Sarcopenia - Pipeline Review, H2 2018

Global Markets Direct’s, ‘Sarcopenia - Pipeline Review, H2 2018’, provides an overview of the Sarcopenia pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Sarcopenia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Sarcopenia and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Sarcopenia

- The report reviews pipeline therapeutics for Sarcopenia by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved Sarcopenia therapeutics and enlists all their major and minor projects

- The report assesses Sarcopenia therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news related to pipeline therapeutics for Sarcopenia

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Sarcopenia

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Sarcopenia pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Amgen Inc

Biophytis SA

Faraday Pharmaceuticals Inc

GlaxoSmithKline Plc

Immusoft Corp

MYOS RENS Technology Inc

Neurotune AG

Novartis AG

Regeneron Pharmaceuticals Inc

ST Pharm Co ...

Amgen Inc

Biophytis SA

Faraday Pharmaceuticals Inc

GlaxoSmithKline Plc

Immusoft Corp

MYOS RENS Technology Inc

Neurotune AG

Novartis AG

Regeneron Pharmaceuticals Inc

ST Pharm Co., Ltd.

Teijin Pharma Ltd

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Sarcopenia - Overview

Sarcopenia - Therapeutics Development

Pipeline Overview

Pipeline by Companies ...

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Sarcopenia - Overview

Sarcopenia - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Sarcopenia - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Sarcopenia - Companies Involved in Therapeutics Development

Amgen Inc

Biophytis SA

Faraday Pharmaceuticals Inc

GlaxoSmithKline Plc

Immusoft Corp

MYOS RENS Technology Inc

Neurotune AG

Novartis AG

Regeneron Pharmaceuticals Inc

ST Pharm Co., Ltd.

Teijin Pharma Ltd

Sarcopenia - Drug Profiles

ARM-210 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ATA-842 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AVGN-7 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

bimagrumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BIO-101 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Biologic for Muscle Wasting Disorders and Sarcopenia - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BVFA-829 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Cell Therapy for Sarcopenia - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Drug to Inhibit SARM1 for Sarcopenia - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NT-1654 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Proteins for Musculoskeletal Disorders - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Recombinant Protein for Sarcopenia - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit Cyclooxygenase 2 for Sarcopenia - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit Furin for Sarcopenia and Cachexia - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit JAK3 for Rheumatoid Arthritis, Sarcopenia and Cachexia - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

sodium iodide - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TEISARM-2 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

trevogrumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Sarcopenia - Dormant Projects

Sarcopenia - Product Development Milestones

Featured News & Press Releases

May 24, 2018: BIOPHYTIS: Inclusion of the First Patient in Phase 2b Study in Sarcopenia

Mar 01, 2018: BIOPHYTIS updates on SARA clinical study of Sarconeos in sarcopenia and presents four posters at the International Conference on Frailty & Sarcopenia Research (ICFSR) in Miami

Dec 08, 2017: Biophytis Presents 4 Posters on Sarconeos at 10th International Conference on Cachexia, Sarcopenia, and Wasting Disorders (SCWD)

Dec 04, 2017: Biophytis has FAMHP Approval to conduct SARA-INT phase 2b Interventional Study of Sarconeos in Sarcopenia in Belgium

Oct 30, 2017: BIOPHYTIS Has FDA Approval to Initiate SARA-INT Phase 2b Interventional Study of Sarconeos in Sarcopenia

Sep 25, 2017: Biophytis filed IND application for approval by FDA of SARA-INT Phase 2b study of Sarconeos in Sarcopenia

May 11, 2017: BIOPHYTIS: First patient-in in the United States and opening of 2 clinical centers for the SARA-OBS study on Sarcopenia

May 03, 2017: BIOPHYTIS confirms that Sarconeos modulates the Renin-Angiotensin System and activates muscular metabolism in the SARA-PK clinical trial

Mar 27, 2017: Biophytis opens the first clinical centers in Europe and starts the recruitment of sarcopenic patients for SARA-OBS study

Mar 21, 2017: BIOPHYTIS to present on BIO101 at the International Conference on Frailty & Sarcopenia Research (ICFSR) in Barcelona

Mar 01, 2017: BIOPHYTIS: Full results of SARA-PK study confirm Sarconeos good pharmacokinetic profile in elderly patients

Dec 16, 2016: Biophytis presents preliminary clinical data of SARA - PK, and new preclinical data of Sarconeos for treating sarcopenia

Nov 29, 2016: BIOPHYTIS Announces Successful Completion of SARA-PK Clinical Study for Sarconeos in Sarcopenia Confirming Safety Profile

Nov 22, 2016: BIOPHYTIS received regulatory authorizations to conduct SARA-OBS study in sarcopenia patients

Nov 15, 2016: BIOPHYTIS Presenting Four Posters on Sarconeos at 9th International Conference on Cachexia, Sarcopenia, and Muscle Wasting

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Sarcopenia, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under ...

List of Tables

Number of Products under Development for Sarcopenia, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under Development by Universities/Institutes, H2 2018

Products under Development by Companies, H2 2018

Products under Development by Universities/Institutes, H2 2018

Number of Products by Stage and Target, H2 2018

Number of Products by Stage and Mechanism of Action, H2 2018

Number of Products by Stage and Route of Administration, H2 2018

Number of Products by Stage and Molecule Type, H2 2018

Sarcopenia - Pipeline by Amgen Inc, H2 2018

Sarcopenia - Pipeline by Biophytis SA, H2 2018

Sarcopenia - Pipeline by Faraday Pharmaceuticals Inc, H2 2018

Sarcopenia - Pipeline by GlaxoSmithKline Plc, H2 2018

Sarcopenia - Pipeline by Immusoft Corp, H2 2018

Sarcopenia - Pipeline by MYOS RENS Technology Inc, H2 2018

Sarcopenia - Pipeline by Neurotune AG, H2 2018

Sarcopenia - Pipeline by Novartis AG, H2 2018

Sarcopenia - Pipeline by Regeneron Pharmaceuticals Inc, H2 2018

Sarcopenia - Pipeline by ST Pharm Co., Ltd. , H2 2018

Sarcopenia - Pipeline by Teijin Pharma Ltd, H2 2018

Sarcopenia - Dormant Projects, H2 2018

List of Figures

List of Figures

Number of Products under Development for Sarcopenia, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under ...

List of Figures

Number of Products under Development for Sarcopenia, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under Development by Universities/Institutes, H2 2018

Number of Products by Top 10 Targets, H2 2018

Number of Products by Stage and Top 10 Targets, H2 2018

Number of Products by Top 10 Mechanism of Actions, H2 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2018

Number of Products by Routes of Administration, H2 2018

Number of Products by Stage and Routes of Administration, H2 2018

Number of Products by Molecule Types, H2 2018

Number of Products by Stage and Molecule Types, H2 2018

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports